GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (FRA:VT6) » Definitions » EV-to-FCF

Voyager Therapeutics (FRA:VT6) EV-to-FCF : 3.57 (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Voyager Therapeutics's Enterprise Value is €250.3 Mil. Voyager Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €70.1 Mil. Therefore, Voyager Therapeutics's EV-to-FCF for today is 3.57.

The historical rank and industry rank for Voyager Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:VT6' s EV-to-FCF Range Over the Past 10 Years
Min: -465.79   Med: -0.76   Max: 233.41
Current: 3.6

During the past 11 years, the highest EV-to-FCF of Voyager Therapeutics was 233.41. The lowest was -465.79. And the median was -0.76.

FRA:VT6's EV-to-FCF is ranked better than
52.88% of 382 companies
in the Biotechnology industry
Industry Median: 5.84 vs FRA:VT6: 3.60

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Voyager Therapeutics's stock price is €7.855. Voyager Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €2.813. Therefore, Voyager Therapeutics's PE Ratio for today is 2.79.


Voyager Therapeutics EV-to-FCF Historical Data

The historical data trend for Voyager Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics EV-to-FCF Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.52 -1.23 -0.26 -9.32 2.16

Voyager Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.32 1.14 2.74 1.26 2.16

Competitive Comparison of Voyager Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Voyager Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's EV-to-FCF falls into.



Voyager Therapeutics EV-to-FCF Calculation

Voyager Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=250.316/70.109
=3.57

Voyager Therapeutics's current Enterprise Value is €250.3 Mil.
Voyager Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €70.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyager Therapeutics  (FRA:VT6) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Voyager Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.855/2.813
=2.79

Voyager Therapeutics's share price for today is €7.855.
Voyager Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.813.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Voyager Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (FRA:VT6) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (FRA:VT6) Headlines

No Headlines